• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Ariad Pharmaceuticals

Ariad Pharmaceuticals

  1. All
  2. 3rd Party
  1. ARIAD Announces Issuance of Key U.S. Patent on Brigatinib

    ARIAD Announces Issuance of Key U.S. Patent on Brigatinib

  2. S&P 500 back for another crack at trendline -2-

    S&P 500 back for another crack at trendline -2-

  3. ARIAD Announces Approval of Iclusig (as Ponatinib Hydrochloride) in Canada

    ARIAD Announces Approval of Iclusig (as Ponatinib Hydrochloride) in Canada

  4. S&P 500's slow-motion breakout attempt remains -2-

    S&P 500's slow-motion breakout attempt remains -2-

  5. UPDATE: S&P 500's slow-motion breakout attempt -2-

    UPDATE: S&P 500's slow-motion breakout attempt -2-

  6. The Top-Performing Funds in 2011's Toughest Category

    These two small-value funds have followed different paths to success in a difficult year for the peer group.

Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.